IBDEI1EO ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25205,1,5,0)
 ;;=5^Hepatitis B, Chronic
 ;;^UTILITY(U,$J,358.3,25205,2)
 ;;=^303249
 ;;^UTILITY(U,$J,358.3,25206,0)
 ;;=070.51^^145^1536^29
 ;;^UTILITY(U,$J,358.3,25206,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25206,1,4,0)
 ;;=4^070.51
 ;;^UTILITY(U,$J,358.3,25206,1,5,0)
 ;;=5^Hepatitis C, Acute
 ;;^UTILITY(U,$J,358.3,25206,2)
 ;;=^266632
 ;;^UTILITY(U,$J,358.3,25207,0)
 ;;=070.54^^145^1536^30
 ;;^UTILITY(U,$J,358.3,25207,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25207,1,4,0)
 ;;=4^070.54
 ;;^UTILITY(U,$J,358.3,25207,1,5,0)
 ;;=5^Hepatitis C, Chronic
 ;;^UTILITY(U,$J,358.3,25207,2)
 ;;=^303252
 ;;^UTILITY(U,$J,358.3,25208,0)
 ;;=571.41^^145^1536^32
 ;;^UTILITY(U,$J,358.3,25208,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25208,1,4,0)
 ;;=4^571.41
 ;;^UTILITY(U,$J,358.3,25208,1,5,0)
 ;;=5^Hepatitis, Chronic Persist
 ;;^UTILITY(U,$J,358.3,25208,2)
 ;;=^259093
 ;;^UTILITY(U,$J,358.3,25209,0)
 ;;=571.1^^145^1536^33
 ;;^UTILITY(U,$J,358.3,25209,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25209,1,4,0)
 ;;=4^571.1
 ;;^UTILITY(U,$J,358.3,25209,1,5,0)
 ;;=5^Hepatitis, ETOH acute
 ;;^UTILITY(U,$J,358.3,25209,2)
 ;;=^2597
 ;;^UTILITY(U,$J,358.3,25210,0)
 ;;=070.59^^145^1536^34
 ;;^UTILITY(U,$J,358.3,25210,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25210,1,4,0)
 ;;=4^070.59
 ;;^UTILITY(U,$J,358.3,25210,1,5,0)
 ;;=5^Hepatitis, Other Viral
 ;;^UTILITY(U,$J,358.3,25210,2)
 ;;=Hepatitis, Other Viral^266631
 ;;^UTILITY(U,$J,358.3,25211,0)
 ;;=V08.^^145^1536^24
 ;;^UTILITY(U,$J,358.3,25211,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25211,1,4,0)
 ;;=4^V08.
 ;;^UTILITY(U,$J,358.3,25211,1,5,0)
 ;;=5^HIV + Status (Asymptomatic)
 ;;^UTILITY(U,$J,358.3,25211,2)
 ;;=HIV + Status (Asymptomatic)^303392
 ;;^UTILITY(U,$J,358.3,25212,0)
 ;;=042.^^145^1536^25
 ;;^UTILITY(U,$J,358.3,25212,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25212,1,4,0)
 ;;=4^042.
 ;;^UTILITY(U,$J,358.3,25212,1,5,0)
 ;;=5^HIV Disease (symptomatic)
 ;;^UTILITY(U,$J,358.3,25212,2)
 ;;=HIV Disease (symptomatic)^266500
 ;;^UTILITY(U,$J,358.3,25213,0)
 ;;=464.00^^145^1536^2
 ;;^UTILITY(U,$J,358.3,25213,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25213,1,4,0)
 ;;=4^464.00
 ;;^UTILITY(U,$J,358.3,25213,1,5,0)
 ;;=5^Acute Laryngitis
 ;;^UTILITY(U,$J,358.3,25213,2)
 ;;=Acute Laryngitis^323469
 ;;^UTILITY(U,$J,358.3,25214,0)
 ;;=790.6^^145^1536^1
 ;;^UTILITY(U,$J,358.3,25214,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25214,1,4,0)
 ;;=4^790.6
 ;;^UTILITY(U,$J,358.3,25214,1,5,0)
 ;;=5^Abnormal LFT's
 ;;^UTILITY(U,$J,358.3,25214,2)
 ;;=^87228
 ;;^UTILITY(U,$J,358.3,25215,0)
 ;;=780.60^^145^1536^20
 ;;^UTILITY(U,$J,358.3,25215,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25215,1,4,0)
 ;;=4^780.60
 ;;^UTILITY(U,$J,358.3,25215,1,5,0)
 ;;=5^Fever
 ;;^UTILITY(U,$J,358.3,25215,2)
 ;;=^336764
 ;;^UTILITY(U,$J,358.3,25216,0)
 ;;=795.51^^145^1536^55
 ;;^UTILITY(U,$J,358.3,25216,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25216,1,4,0)
 ;;=4^795.51
 ;;^UTILITY(U,$J,358.3,25216,1,5,0)
 ;;=5^Pos PPD w/o Active TB
 ;;^UTILITY(U,$J,358.3,25216,2)
 ;;=^340572
 ;;^UTILITY(U,$J,358.3,25217,0)
 ;;=482.9^^145^1536^53
 ;;^UTILITY(U,$J,358.3,25217,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25217,1,4,0)
 ;;=4^482.9
 ;;^UTILITY(U,$J,358.3,25217,1,5,0)
 ;;=5^Pneumonia,Bacterial
 ;;^UTILITY(U,$J,358.3,25217,2)
 ;;=^12347
 ;;^UTILITY(U,$J,358.3,25218,0)
 ;;=571.42^^145^1536^31
 ;;^UTILITY(U,$J,358.3,25218,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25218,1,4,0)
 ;;=4^571.42
 ;;^UTILITY(U,$J,358.3,25218,1,5,0)
 ;;=5^Hepatitis, Autoimunne
 ;;^UTILITY(U,$J,358.3,25218,2)
 ;;=^336610
